Lantheus Holdings (LNTH) Return on Capital Employed (2015 - 2026)
Lantheus Holdings' (LNTH) quarterly Return on Capital Employed came in at 14.85% in Q1 2026, down 1072.0% year-on-year from 1.53% in Q1 2025, and down 8.36% on a QoQ basis from 16.2% in Q4 2025.
Lantheus Holdings (LNTH) Return on Capital Employed (2015 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 12 years of Return on Capital Employed data on file, last reported at 14.85% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 1072.0% year-over-year to 14.85% in Q1 2026; TTM through Mar 2026 was 14.85%, a 1072.0% decrease from a year earlier, with the FY2025 full-year figure at 17.56%, down 1145.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 14.85%, down from 16.2% in the prior quarter.
- Over the last five years, Return on Capital Employed for LNTH reached as high as 39.7% in Q3 2024 and fell as low as 3.03% in Q1 2023.
- Historically, Return on Capital Employed has averaged 16.9% across 5 years, with a median of 18.79% in 2025.
- Across the five-year window, Return on Capital Employed surged 3527 bps in 2024 and sank 2091 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 3.77% in 2022, then jumped by 592 bps to 26.06% in 2023, then dropped by 1 bps to 25.75% in 2024, then slumped by 37 bps to 16.2% in 2025, then decreased by 8 bps to 14.85% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 14.85% in Q1 2026, 16.2% in Q4 2025, and 18.79% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 14.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.85% |
| Dec 31, 2025 | 16.20% |
| Sep 30, 2025 | 18.79% |
| Jun 30, 2025 | 24.24% |
| Mar 31, 2025 | 25.56% |
| Dec 31, 2024 | 25.75% |
| Sep 30, 2024 | 39.70% |
| Jun 30, 2024 | 28.31% |
| Mar 31, 2024 | 31.96% |
| Dec 31, 2023 | 26.06% |
| Sep 30, 2023 | 4.43% |
| Jun 30, 2023 | 2.43% |
| Mar 31, 2023 | -3.03% |
| Dec 31, 2022 | 3.77% |
| Sep 30, 2022 | 21.07% |
| Jun 30, 2022 | 9.60% |
| Mar 31, 2022 | -2.43% |
| Dec 31, 2021 | -7.95% |
| Sep 30, 2021 | -3.35% |
| Jun 30, 2021 | -2.18% |